Results 71 to 80 of about 6,317 (201)

An early Indian experience with benralizumab - A compendium on severe asthma cases: a case series [version 1; peer review: 2 approved]

open access: yesF1000Research, 2023
Background: Severe eosinophilic asthma (SEA), one of the phenotypes of asthma that is characterized by elevated blood eosinophil counts, is a common cause of uncontrolled asthma.
Priti Meshram   +5 more
doaj   +1 more source

Longitudinal stability of asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study [PDF]

open access: yes, 2016
BACKGROUND: Asthma is a biologically heterogeneous disease and development of novel therapeutics requires understanding of pathophysiologic phenotypes. There is uncertainty regarding the stability of clinical characteristics and biomarkers in asthma over
C. Porsbjerg   +16 more
core   +1 more source

Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis

open access: yesMedicina, 2019
A 56-year-old man with severe asthma underwent bronchial thermoplasty (BT). However, his asthma exacerbated and hypereosinophilia developed 2 months later, thus necessitating oral corticosteroid (OCS) therapy.
Hiroaki Tsurumaki   +7 more
doaj   +1 more source

Benralizumab use in chronic eosinophilic pneumonia with eosinophilic bronchiolitis and chronic airway infection

open access: yesRespirology Case Reports, 2021
Chronic eosinophilic pneumonia (CEP) is a rare disorder characterized by marked accumulation of eosinophils in lung tissues and/or bronchoalveolar lavage fluid (BALF). Patients with CEP usually respond well to corticosteroids.
Tomotsugu Takano   +4 more
doaj   +1 more source

Overlapping forms of granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis: Insights from a European multicenter study

open access: yesJournal of Internal Medicine, Volume 299, Issue 3, Page 349-364, March 2026.
Abstract Background Granulomatosis with polyangiitis (GPA) and eosinophilic granulomatosis with polyangiitis (EGPA) are distinct forms of antineutrophil cytoplasm antibody (ANCA)‐associated vasculitis (AAV). Increasing evidence suggests overlapping features, particularly in proteinase 3 (PR3)‐ANCA‐positive EGPA and GPA with eosinophilia.
Federica Pallotti   +45 more
wiley   +1 more source

Importance of Smell Loss to Patients With Chronic Rhinosinusitis With Nasal Polyps: Options for Management and Recovery

open access: yesClinical and Translational Allergy, Volume 16, Issue 2, February 2026.
ABSTRACT Primary diffuse type 2‐dominant chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disease of the nasal cavity and paranasal sinuses associated with significant morbidity. Impaired sense of smell is a cardinal symptom of CRSwNP and one of the most burdensome for patients, impacting quality of life, mental health, and even ...
Thomas S. Higgins   +9 more
wiley   +1 more source

Current Insights Into Individualized Diagnosis and Treatment of Allergic Rhinitis Based on Phenotype and Endotype

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, Volume 12, Issue 1, Page 124-135, February 2026.
ABSTRACT Allergic rhinitis (AR) is a chronic inflammatory disease of the nasal mucosa characterized by allergen sensitization and the involvement of multiple inflammatory mediators. Currently, the treatment of AR mainly includes symptomatic relief, anti‐inflammatory therapy, and nerve desensitization. However, these treatments have limitations in fully
Yue Gu   +7 more
wiley   +1 more source

Real‐World Treatment Patterns in AERD: An Analysis of ATAD, Biologics, and Combination Therapy

open access: yesInternational Forum of Allergy &Rhinology, Volume 16, Issue 1, Page 99-101, January 2026.
Key Points Contemporary aspirin exacerbated respiratory disorder (AERD) therapy commonly includes aspirin desensitization (55%) and biologics (48%). Aspirin desensitization therapy has higher discontinuation rates than biologics. Patients receiving biologics are younger, and ∼25% of the patients switch to other agents.
Nitish Kumar   +5 more
wiley   +1 more source

Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study [PDF]

open access: yes
Purpose: Severe eosinophilic asthma (SEA) patients often present overlapping inflammatory features rendering them eligible for multiple biologic therapies; switching biologic treatment is a strategy adopted to optimize asthma control when patients show ...
Cameli, Paolo   +2 more
core   +8 more sources

Home - About - Disclaimer - Privacy